RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+25.68%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.77B
AUM Growth
+$6.77B
(+5.8%)
Cap. Flow
-$132M
Cap. Flow
% of AUM
-1.95%
Top 10 Holdings %
Top 10 Hldgs %
45.13%
Holding
79
New
15
Increased
25
Reduced
7
Closed
10
Top Buys
| 1 |
Stryker
SYK
|
$115M |
| 2 |
Immatics
IMTX
|
$89.5M |
| 3 |
Dyne Therapeutics
DYN
|
$87.8M |
| 4 |
Merus
MRUS
|
$78.2M |
| 5 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$72.8M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$398M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$314M |
| 3 |
Celldex Therapeutics
CLDX
|
$137M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$112M |
| 5 |
Vericel Corp
VCEL
|
$83.6M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Financials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rocket Pharmaceuticals
RCKT
$354M
| $477M | 7.03% | 17,687,772 | – | – |
|
2
Immunocore
IMCR
$1.62B
| $391M | 5.78% | 6,019,641 -76,746 | -1% | -$4.99M |
|
3
Axsome Therapeutics
AXSM
$6.05B
| $359M | 5.29% | 4,492,679 +3,083 | +0.1% | +$246K |
|
4
Ultragenyx Pharmaceutical
RARE
$2.89B
| $331M | 4.88% | 7,087,115 +200,029 | +3% | +$9.34M |
|
5
Bruker
BRKR
$5.16B
| $314M | 4.64% | 3,344,095 | – | – |
|
6
argenx
ARGX
$43.6B
| $263M | 3.88% | 667,195 | – | – |
|
7
Acadia Pharmaceuticals
ACAD
$4.38B
| $256M | 3.77% | 13,829,315 +2,575,764 | +23% | +$47.6M |
|
8
Natera
NTRA
$23.1B
| $237M | 3.5% | 2,593,323 | – | – |
|
9
PTC Therapeutics
PTCT
$3.92B
| $216M | 3.19% | 7,423,970 | – | – |
|
10
Masimo
MASI
$7.59B
| $215M | 3.17% | 1,462,400 | – | – |
|
11
Avidity Biosciences
RNA
$5.99B
| $203M | 3% | 7,970,269 +1,280,480 | +19% | +$32.7M |
|
|
12
Merus
MRUS
$4.98B
| $185M | 2.73% | 4,109,393 +1,735,768 | +73% | +$78.2M |
|
13
Cytokinetics
CYTK
$4.23B
| $177M | 2.61% | 2,525,080 | – | – |
|
14
Apogee Therapeutics
APGE
$2.17B
| $164M | 2.42% | 2,467,591 +325,000 | +15% | +$21.6M |
|
15
Alkermes
ALKS
$4.78B
| $164M | 2.42% | 6,054,280 +2,152,757 | +55% | +$58.3M |
|
16
Protagonist Therapeutics
PTGX
$3.67B
| $154M | 2.27% | 5,315,514 | – | – |
|
17
Penumbra
PEN
$10.6B
| $151M | 2.23% | 675,888 +13,224 | +2% | +$2.95M |
|
|
AVDL
18
Avadel Pharmaceuticals
AVDL
$1.43B
| $149M | 2.19% | 8,798,558 +1,850,640 | +27% | +$31.3M |
|
19
Akero Therapeutics
AKRO
$3.74B
| $137M | 2.03% | 5,431,985 +1,839,226 | +51% | +$46.5M |
|
20
Establishment Labs
ESTA
$1.2B
| $136M | 2.01% | 2,675,703 +181,565 | +7% | +$9.24M |
|
21
Arvinas
ARVN
$568M
| $136M | 2.01% | 3,297,897 -915,586 | -22% | -$37.8M |
|
22
Tarsus Pharmaceuticals
TARS
$2.47B
| $119M | 1.76% | 3,272,341 +120,000 | +4% | +$4.36M |
|
|
23
Stryker
SYK
$150B
| $115M | 1.7% | +321,000 | New | +$115M |
|
|
24
Madrigal Pharmaceuticals
MDGL
$9.76B
| $106M | 1.57% | 397,047 -418,144 | -51% | -$112M |
|
|
25
Immatics
IMTX
$619M
| $105M | 1.55% | 10,000,000 +8,515,089 | +573% | +$89.5M |
|